Annual report [Section 13 and 15(d), not S-K Item 405]

Revenue Recognition, Collaboration Agreements, and Other Research and Development Agreements (Details Narrative)

v3.25.1
Revenue Recognition, Collaboration Agreements, and Other Research and Development Agreements (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Apr. 08, 2022
Nov. 19, 2021
Nov. 19, 2020
Dec. 12, 2019
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Therapeutics development award         $ 1,096  
License Agreement Terms [Member]              
License agreement description         The Second Amended and Restated Exclusive License Agreement provides for, among other things, the payment of (1) royalties on a tiered basis between low single digits and the mid-single digits of net sales of products using such licensed technology, (2) a one-time sales milestone fee of $100 when and if sales of products using the licensed technology reach the specified sales threshold and (3) an annual license fee of $50 over the term of the License Agreement. The term of the License Agreement will remain in effect until the expiration of the last-to-expire patent rights licensed or seven and one-half years from the date of the first commercial sale of a licensed product under this agreement, whichever is later    
Cystic Fibrosis Foundation Therapeutics Development Award [Member]              
Research and development, costs incurred         $ 0 88  
BioNTech Agreement [Member]              
Revenue recognized $ 2,750            
BioNTech Agreement [Member] | License and Service [Member]              
Revenue recognized           688  
BioNTech Agreement [Member] | Health Care, Patient Service [Member]              
Revenue recognized           375  
CFF Agreement [Member]              
Grants receivable           3,635  
Additional milestone payment           $ 4,555  
CFF Agreement [Member] | Accrued Liabilities [Member]              
Other Liabilities             $ 88
CFF Agreement [Member] | Cystic Fibrosis Foundation [Member] | Cystic Fibrosis Foundation Therapeutics Development Award [Member]              
Therapeutics development award     $ 4,234        
Previously received awards     $ 484        
Additional milestone payment   $ 321          
Genentech Feasibility Study Agreement [Member]              
Revenue recognized       $ 33      
Genentech Feasibility Study Agreement [Member] | Three Molecules [Member]              
Revenue recognized       $ 100